KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Yuxiang Ma, Wenfeng Fang, Yang Zhang, Yunpeng Yang, Shaodong Hong, Yuanyuan Zhao, Shuang Xie, Jun Ge, Hao Jin Zhou, Hongyun Zhao, Li Zhang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Lessons Learned: Results of the KEYNOTE-032 study showed that the safety and pharmacokinetic profiles of pembrolizumab in Chinese patients were comparable with those observed in international studies, and antitumor activity was encouraging. These data support further evaluation of pembrolizumab to improve clinical outcomes in Chinese patients with advanced non-small cell lung cancer. Background: The KEYNOTE-032 study evaluated pembrolizumab pharmacokinetics and clinical outcomes in Chinese patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) and prior treatment failure and/or ineligibility for standard therapy. Methods: Patients were randomized 1:1:1 to pembrolizumab 2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks (up to 35 cycles). Safety and pharmacokinetics were primary endpoints; antitumor activity was a secondary endpoint. Results: A total of 42 of 44 randomized patients received pembrolizumab treatment (2 mg/kg, n = 14; 10 mg/kg, n = 13; 200 mg, n = 15). Treatment-related adverse events (AEs) occurred in 29 of 42 (69%) patients (grade 3–4, 4/42 [10%]); 5 (12%) had immune-mediated AEs and infusion reactions. Pembrolizumab single dose half-life following 2 mg/kg, 10 mg/kg, and 200 mg was 15.1, 15.8, and 12.3 days, respectively. Serum exposure at the doses studied (range, 2–10 mg/kg) was approximately linear; steady-state area under the curve0–21 days (95% confidence interval [CI]) was 730.9 (627.4–851.6), 2,819.2 (2,009.4–3,955.4), and 931.0 (724.4–1,196.6) μg•day/mL, respectively. After 7.9 (range, 0.7–13.1) months median follow-up overall, objective response rate was 14.3% (95% CI, 5.4%–28.5%); median progression-free survival was 2.1 (95% CI, 2.1–4.2) months, and median overall survival was not reached (95% CI, 6.6 months–not reached). Conclusion: Pembrolizumab had manageable toxicity, linear serum exposure, and encouraging antitumor activity in Chinese patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)650-e1145
Issue number8
Publication statusPublished - 1 Aug 2020
Externally publishedYes


Dive into the research topics of 'KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this